BIOHIT OYJ STOCK EXCHANGE RELEASE 26 JANUARY 2007 BIOHIT PLANS TO INCORPORATE ITS DIAGNOSTICS BUSINESS At a meeting held on Friday 26 January 2007, Biohit Oyjs Board of Directors decided to investigate the possibility of hiving off the companys diagnostics business into a separate limited company. The purpose is also to obtain its own equity in order to boost international marketing and distribution and thereby rapidly and effectively leverage the significant potential of existing and forthcoming products. The decision forms part of the companys new strategy, which aims to clarify the differences and synergies between its business areas and derive the full benefit from their strengths, as well as to boost the Groups business as a whole and improve earnings. Biohit Oyj currently operates in two business segments: the liquid handling business and the diagnostics business. The companys liquid handling business develops, manufactures and markets laboratory equipment and supplies for use in the pharmaceutical, food and other industries, as well as for use in research institutions, universities and hospitals, and to complement the diagnostic and analysis systems of many other companies, such as 3M, bioMérieux and three Johnson&Johnson Group companies. Biohits diagnostics business primarily develops, manufactures and markets products and analysis systems for diagnosing, screening for and preventing gastrointestinal diseases. The product range includes Biohits patented GastroPanel examination a test that from a blood sample diagnoses diseases of the gastric mucosa and their associated risks (see, for example, www.gastropanel.net, www.biohit.com / Diagnostics). Biohits business segments differ in, for example, their market situations and customer bases, distribution channels and marketing, and production processes. When the diagnostics business is hived off into a separate company, both businesses will be better able to focus on developing their own strengths. When established, the new company will focus primarily on developing, manufacturing and marketing diagnostics tests and analyses systems for diagnosing, screening for and preventing diseases of the digestive tract. It will also develop, manufacture and market products for eliminating carcinogenic substances (see www.biohit.com / Investors / Stock Exchange Releases: 5 January 2007). Biohit Oyj Board of Directors For additional information, contact: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 Mobile: +358-40-745 5605 Email: osmo.suovaniemi@biohit.com Distribution: Helsinki Exchanges Financial Supervisory Authority Press http://www.biohit.com